CSIMarket
 


Xortx Therapeutics Inc   (XRTX)
Other Ticker:  
 

Cumulative Xortx Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

XRTX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

XRTX Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2021)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter

Y / Y Current Liabilities Growth - - - - -
Y / Y Current Assets Growth - - - - -
Working Capital Ratio for Trailing Twelve Months Period 28.78 28.78 28.78 28.78 -
Total Ranking # 143 # # # #
Seq. Current Liabilities Growth 0 % 0 % 0 % - -
Seq. Current Assets Growth 0 % 0 % 0 % - -


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2021
On the trailing twelve months basis Despite unchange in Current Liabilities in the IV. Quarter to $1 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period remained unchanged at 28.78 below Xortx Therapeutics Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Xortx Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about XRTX
Working Capital Ratio XRTX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 35
Sector # 54
S&P 500 # 133


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
28.78 28.78 28.78
(Dec 31 2021)  




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Altimmune Inc   78.09 
Turning Point Therapeutics Inc.  77.07 
Decibel Therapeutics Inc   73.95 
Aptinyx Inc   73.81 
Tyra Biosciences Inc   73.66 
Barinthus Biotherapeutics Plc  72.71 
Innoviva Inc   72.51 
Atossa Therapeutics Inc   68.90 
Cincor Pharma Inc   68.63 
Terns Pharmaceuticals Inc   68.33 
Zomedica Corp   67.45 
Greenwich Lifesciences Inc   66.77 
Anebulo Pharmaceuticals Inc   60.01 
Nuvation Bio Inc   59.66 
Aerovate Therapeutics Inc   56.07 
Annovis Bio inc   55.27 
Infinity Pharmaceuticals Inc   53.19 
Essa Pharma inc   52.98 
Reviva Pharmaceuticals Holdings Inc   51.33 
Lexaria Bioscience Corp   50.95 
Eqrx Inc   44.19 
Cocrystal Pharma Inc   43.69 
Day One Biopharmaceuticals Inc   40.31 
Genprex Inc   40.22 
Sensei Biotherapeutics Inc   40.13 
Olema Pharmaceuticals inc   40.06 
Edgewise Therapeutics inc   38.66 
Karuna Therapeutics Inc   38.40 
Nuvalent Inc   38.12 
Cassava Sciences Inc  36.27 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com